Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T13:35:32.333Z.
Calculation as of: 2026-10-06T13:35:32.333Z.
Quote observation: 2026-10-06T13:34:42.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d88ebff11657cb0645ea93f74423bc241bf41286751ec96f31399ab1bd3406dc
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$8.69M
Price/OCF Ratio
N/A
TTM Avg
9.84
3Y Avg
9.84
5Y Avg
9.84
Market Cap
$7.44M
Price/OCF Ratio
N/A
TTM Avg
41006.18
3Y Avg
41006.18
5Y Avg
41006.18
Market Cap
$9.14M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.09M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aprea Therapeutics, Inc. (APRE) | $8.26M | N/A | N/A | N/A | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $8.02M | N/A | N/A | N/A | N/A |
| HeartSciences Inc. (HSCS)vs › | $7.90M | N/A | N/A | N/A | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.69M | N/A | 9.84 | 9.84 | 9.84 |
| GT Biopharma, Inc. (GTBP)vs › | $7.84M | N/A | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.52M | N/A | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.44M | N/A | 41006.18 | 41006.18 | 41006.18 |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $9.14M | N/A | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.09M | N/A | N/A | N/A | N/A |
| SeaStar Medical Holding Corporation (ICU)vs › | $9.62M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
